Arena Pharmaceutical Inc. (ARNA) announced after the bell Monday that its Phase 2 study of etrasimod met its primary and all secondary endpoints with statistical significance for patients receiving 2 mg dose.
from RTT - Before the Bell http://ift.tt/2GeH1z7
via IFTTT
No comments:
Post a Comment